NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of Perfectus Biomed Group, a UK-based laboratory providing customized microbiological services.
Founded in 2012, Perfectus Biomed Group’s mission is to improve the quality of life through the delivery of exceptional, customized microbiological services to the Medtech Industry. Perfectus, considered a leader in the United Kingdom Accreditation Body (UKAS) ISO 17025 biofilm testing industry, is focused on building strong Client relationships and providing exceptional service. With unique expertise in the development and accreditation of models that represent real-world scenarios, the organization has experienced an exciting growth trajectory over the last ten years which includes an enhanced geographical foothold and biological solutions for novel devices.
Mark White, Investment Director at UKI2S, said, “We are delighted that Perfectus Biomed, based at SciTech Daresbury near Warrington, has been bought by NAMSA, a US based provider of healthcare services and will form a core part of their expansion into Europe. We have been with Sam Westgate and the Perfectus team since day one, when Sam sat down with us to explain her vision for a specialist provider of microbiological testing and related services.
“At that stage the company consisted of just Sam and her ambition so we knew we were, above all, backing the individual. We don’t always get these things right but this time we did, and the growth of Perfectus has been a real pleasure to watch and to share in. The company now employs over 30 people, including the US operation, and is very well placed to expand further under its new ownership. We would happily have stayed involved but think that, on balance, it is probably the right time for the company to become part of a larger group. We wish Sam and the team all the best in their new environment and will watch their development with interest.”
“NAMSA very much looks forward to expanding its European suite of laboratory services with the addition of Perfectus Biomed Group,” commented Dr. Christophe Berthoux, NAMSA CEO. “Perfectus brings an unmatched level of expertise and depth of knowledge in customized microbiological testing solutions. This know-how and extreme proficiency in microbiological research will help us further support Clients and continue to provide cutting-edge solutions for medical device testing and research,” Dr. Berthoux concluded.
As the global leader of the medical device testing industry since 1967, NAMSA has amassed a large breadth and depth of therapeutic expertise and knowledge across the continuum of microbiology and in vitro testing services. NAMSA’s world-class testing capabilities include all areas of microbiological sterility, validation and quality assurance solutions in well-equipped facilities throughout North America and Europe.
“Perfectus Biomed Group is delighted to join NAMSA in its mission to deliver best-in-class global MedTech solutions through its people, expertise and technology. With similar values and expertise in customizing solutions for Clients across the globe, we are well-aligned to achieve future success for both Clients and our combined organizations,” stated Dr. Samantha Westgate, Perfectus Biomed Group CEO. “With the complimentary expertise and resources of NAMSA, we will serve our Clients in an even greater capacity and we look forward to joining the world’s leading CRO for full continuum development services,” Dr. Westgate concluded.
The acquisition of Perfectus Biomed Group increases NAMSA’s scale in the UK and growing global presence, now serving Clients in over 20 locations across the Americas, Asia and Europe.
The price and terms of the transaction are undisclosed.